Pain Response And Health-Related Quality Of Life (Hrql) Analysis In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Receiving Cabazitaxel (Cbz) Versus Abiraterone Or Enzalutamide In The Card Study

Karim Fizazi,Gero Kramer,Jean-Christophe Eymard, Johann S. De Bono,Cora N. Sternberg,Bertrand F. Tombal,Daniel Castellano,Christian Wülfing,Michail Liontos,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Asgerour Sverrisdottir,Christine Theodore,Susan Feyerabend,Carole Helissey,Pascaline Picard,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Ronald De Wit

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 15|浏览79

暂无评分

摘要

16Background: The CARD NCT02485691 study reported superior rPFS and OS with CBZ vs abiraterone or enzalutamide in patients with mCRPC who progressed on docetaxel and within 12 months on a previous ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要